CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 42 enrolled
Drug / intervention
lasmiditan 200 mg +2 moredrug
Likely dose
lasmiditan 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03076970
NCT03076970Phase 1Completed
CompareCT.gov

A Randomized, Double-Blind, Three Period, Cross-Over Study to Evaluate the Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan (Imitrex) in Healthy Male and Female Subjects

Eli Lilly and Company·interventional·Posted Mar 10, 2017·Updated Dec 2, 2019

In Brief

A Phase 1 clinical trial evaluating lasmiditan 200 mg, Sumatriptan, and 1 other intervention for Migraine. Completed, enrolled 42 participants across 1 site.

Detailed Summary

This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of lasmiditan 200 mg.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine
CountriesUnited States
CollaboratorsSNBL Clinical Pharmacology Center, Inc., CoLucid Pharmaceuticals

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 10, 2017
Enrollment StartMar 21, 2017
Primary CompletionApr 13, 2017
TodayJul 2, 2026
Enrollment to primary: 22 daysPosted 9.3 years ago

Interventions

lasmiditan 200 mgdrug

drug including single placebo tablet

Sumatriptandrug

drug including single placebo tablet

matching placebodrug

single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.